Efficacy of a Multi-strain Probiotic in the Treatment of Irritable Bowel Syndrome (IBS)

Irritable Bowel Syndrome Clinical Trial

Official title:

The Effect of Kyo-Dophilus 1.5 Billion on the Symptoms of Irritable Bowel Syndrome (IBS)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01176227
• Other study ID #: 1001
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: May 31, 2010
• Last updated: March 31, 2011
• Start date: May 2010
• Est. completion date: February 2011

Study information

• Verified date: March 2011
• Source: The Canadian College of Naturopathic Medicine
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

The Canadian College of Naturopathic Medicine is conducting a research study on Irritable Bowel Syndrome (IBS), a common condition in North America. It is a long term, recurring gastrointestinal disorder that is estimated to affect 30% of the general population. IBS is characterized by abdominal pain and cramps, and bowel dysfunction such as diarrhea and bloating.

The medicines that are currently used to help people with IBS are not as effective as we would like them to be. These medicines are usually only prescribed to reduce the pain of IBS and not actually treat the disorder itself. Recently, scientists have found that probiotics (beneficial bacteria that live inside humans) may help reduce the painful symptoms and diarrhea that are part of IBS.

This research is being conducted to determine whether this particular combination of three probiotic bacteria (named Lactobacillus gasseri, Bifidobacterium bifidum and Bifidobacterium longum) will reduce the symptoms of IBS.

Description:

The purpose of this trial is to investigate the effects of the three strain probiotic, Kyo-Dophilus, on the symptoms associated with Irritable Bowel Syndrome.

The primary objective of this trial is to determine the effectiveness of Kyo-Dophilus on the symptoms associated with Irritable Bowel Syndrome in an adult population diagnosed with Irritable Bowel Syndrome by ROME III criteria and classified as mild through the Irritable Bowel Severity Scoring System and to measuring quality of life and global well being of patients through the Visual Analog Scale and the Irritable Bowel Syndrome-Quality of Life Questioner. The secondary objective is to assess the tolerability of the treatment through the use of study diaries.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 128
• Est. completion date: February 2011
• Est. primary completion date: February 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

• Male and female subjects aged 18-64

• A diagnosis of Irritable Bowel Syndrome as per ROME III criteria

• A classification of mild irritable bowel syndrome as indicated by the Irritable Bowel Severity Scoring System (score >75)

• Female subjects currently using an acceptable form of birth control who agree to maintain its use throughout the study (e.g. abstinence, oral contraceptives, barrier methods)

• Subjects who agree to maintain their current eating habits throughout the study

• Ability to understand and sign the Informed Consent Form

Exclusion Criteria:

• Female subjects who are breastfeeding, pregnant, or are open to becoming pregnant in the next three months

• Subjects currently receiving medication for the treatment of IBS symptoms

• Subjects currently receiving natural health products for treatment of IBS symptoms will be eligible for inclusion in the trial is they agree to undergo a two week washout period

• Subjects currently experiencing nausea, fever, vomiting, bloody diarrhea or severe abdominal pain

• Subjects who are immune-compromised (e.g. AIDS, lymphoma, patients undergoing long-term corticosteroid treatment)

• Subjects currently receiving antibiotic therapy or antibiotic therapy within the previous month

• Subjects regularly consuming probiotic containing products (e.g. yogurts, etc.)

• Subjects who have recently (< 3 months) initiated dietary measures to control IBS symptoms

• Subjects with a history of major or complicated gastrointestinal surgery

• Subjects with severe endometriosis

• Subjects with malignant tumors or subjects undergoing chemotherapy or radiation therapy

• Subjects with severe IBS and that require medication

• Subjects with weight loss, anaemia, inflammatory bowel disease, celiac sprue, family history of colorectal cancer

• Subjects exhibiting or indicating thoughts of suicide currently or in the past as based on patient screening interview by the investigator/clinician. Appropriate referral to a health care provider will be provided

• Subjects with known allergies to milk or milk based products

• Subjects using and/or have used antipsychotic or anticholinergic medication within the prior month, those with reported significant abnormalities on the thyroid function tests, blood counts and serum chemistry

• Subjects 50 years or older who have been diagnosed with IBS and have not received a colonoscopy in the last five years.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Colitis, Mucous
• Colon, Irritable
• Colonic Diseases
• Colonic Diseases, Functional
• Digestive System Diseases
• Gastrointestinal Diseases
• Irritable Bowel Syndrome
• Syndrome

Intervention

Dietary Supplement:
• Kyodophilus multi-strain probiotic capsules
The Kyo-Dophilus study product is a gelatin capsule containing three proprietary probiotic bacterial strains. The total quantity of bacteria per capsule is 1.5 billion colony forming units (1.5 x 109 cfu) and is composed of the following strains: Lactobacillus gasseri KS-13 1.2 Bifidobacterium bifidum G9-1 0.15 Bifidobacterium longum MM-2 0.15 Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2.
• Kyodophilus Matching Placebo Capsules
Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2.

Locations

Country	Name	City	State
Canada	The Canadian College of Naturopathic Medicine	Toronto	Ontario

Sponsors (3)

Lead Sponsor	Collaborator
The Canadian College of Naturopathic Medicine	Dicentra Inc., Wakunaga Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The irrtable bowel severity scoring system is the primary outcome measure	Irritable bowel severity scoring system is a validated questionnaire used to monitor IBS (Francis et al, 1997).	12 weeks (between baseline and end of study)	No
Secondary	Tolerability of the treatment will be assessed through the use of study diaries in which adverse events will be recorded.		12 weeks	Yes
Secondary	The Irritable Bowel Syndrome-Quality of Life Questionnaire	This is a validated quality of life questionnaire (Patrick et al, 1998)	12 weeks (baseline and end of study)	No
Secondary	Visual Analogue Scale	Patient rated 0-6 (7 point)questionnaire on the severity of IBS symptoms	12 weeks (baseline and end of study)	No